Pelacarsen does not reduce CV events in patients with high Lp(a)

Coverage, in order

1. 4d ago
   
   Healio indie

   Pelacarsen does not reduce CV events in patients with high Lp(a)

   CHICAGO — In patients with cardiovascular disease and high lipoprotein(a), pelacarsen did not reduce risk for major adverse CV events compared with placebo, according to results of the Lp(a)HORIZON trial. As Healio previously reported in September, Ionis and Novartis, the developers of pelacarsen…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.